What contributed to the Adjusted EBITDA of $58.3 million and how does this compare to previous quarters? | AMN (Aug 07, 2025) | Candlesense

What contributed to the Adjusted EBITDA of $58.3 million and how does this compare to previous quarters?

What drove the Adjusted EBITDA of $58.3 million

The press release tells us that AMN Healthcare generated $658 million in quarterly revenue and posted an Adjusted EBITDA of $58.3 million for the second quarter of 2025. While the release does not item‑by‑item break out the components of that adjusted EBITDA, a few points can be inferred from the figures that are provided:

Metric What it suggests about the EBITDA driver
Revenue of $658 million The bulk of the adjusted EBITDA comes from the company’s core operating activities—primarily the placement of health‑care professionals and related staffing services. Higher revenue typically translates into a larger EBITDA margin, assuming cost structures remain stable.
GAAP loss of ($3.02) per share A GAAP loss indicates that, after accounting for all standard expenses (including depreciation, amortization, interest, taxes, and any non‑recurring items), the company is still negative on a per‑share basis. The fact that Adjusted EBITDA is positive ($58.3 million) shows that the loss is largely driven by accounting items that are excluded in the “adjusted” calculation (e.g., depreciation, amortization, stock‑based compensation, or other non‑cash charges).
Adjusted EPS of $0.30 The adjusted earnings per share figure is derived from the same adjusted EBITDA base, confirming that the $58.3 million figure is a key contributor to the modest positive adjusted earnings.

In short, the primary contributor to the $58.3 million Adjusted EBITDA is the operating performance of AMN’s staffing and workforce‑solution businesses that generated $658 million in revenue, while the adjustment removes GAAP‑level expenses that otherwise push the company into a per‑share loss.


How this compares to previous quarters

The release does not provide the Adjusted EBITDA numbers for the first quarter of 2025 (or any earlier quarters) and therefore we cannot state definitively whether the $58.3 million figure represents an increase, a decrease, or a flat trend relative to those periods.

What we can say, based on the information at hand:

Comparison element Available information
Adjusted EBITDA this quarter $58.3 million
Adjusted EBITDA prior quarters Not disclosed in the release
Trend insight Because the press release highlights the adjusted EBITDA as a positive figure alongside a GAAP loss per share, it suggests management wants to emphasize that the operating cash‑generation side of the business remains solid. However, without the actual prior‑quarter numbers, we cannot quantify the change.

Bottom line:

- The $58.3 million Adjusted EBITDA is driven mainly by the $658 million of revenue generated from AMN’s core staffing operations, with GAAP‑level expenses (depreciation, amortization, interest, taxes, etc.) excluded in the adjustment.

- The release does not supply Adjusted EBITDA figures for earlier quarters, so a direct quarter‑to‑quarter comparison cannot be made from the provided data. Any assessment of trend would require those historical numbers, which are not included in the current news excerpt.

Other Questions About This News

What macro‑economic factors (e.g., labor market conditions, healthcare spending, staffing demand) could influence future results? How did the company’s operating margin change year‑over‑year and what cost drivers are influencing it? Did the company provide guidance for Q3 2025 revenue, EPS, and Adjusted EBITDA, and how does that compare to analyst expectations? What were the main drivers behind the GAAP loss of $3.02 per share? What are the implications of the GAAP loss versus the positive adjusted EPS for valuation metrics (P/E, EV/EBITDA), and how might investors re‑price the stock? How does AMN’s Q2 performance compare to peers such as Cross Country Healthcare, Envision Healthcare, or other staffing firms? How did AMN Healthcare’s Q2 2025 revenue of $658 million compare to consensus estimates? Did AMN disclose any changes to its capital allocation strategy—share repurchases, dividends, or acquisitions? Did the earnings release mention any regulatory or policy changes that may affect revenue or margins? What was the consensus EPS estimate for Q2 2025 and how does the reported adjusted EPS of $0.30 compare? What changes in key operational metrics (e.g., placements, revenue per employee, utilization rates) were highlighted that could affect future performance? What is the current analyst consensus on the stock after the release—upgrades, downgrades, or rating changes? What full‑year 2025 guidance did AMN give for revenue, profit and cash flow, and how does it align with market expectations? Are there any updates to the company’s debt profile, cash balance, or liquidity position? What was the immediate market reaction (price movement, volume) to the release and how does that compare to typical earnings reactions for AMN?